Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adolescent ADHD Patients

NCT02139111 is registered in ClinicalTrials.gov with Rhodes Pharmaceuticals, L.P. as lead sponsor.

NCT NCT02139111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02139111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adolescent ADHD Patients
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2014
Completion date
May 31, 2015
Enrollment
360 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

adhd